Regeneron Pharmaceuticals And Telix Pharmaceuticals Partner To Develop And Commercialize Next-Generation Radiopharmaceutical Cancer Therapies

Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited have entered into a new collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. The partnership brings together Regeneron’s deep expertise in biologics and antibody discovery with Telix’s established strengths in radiopharmaceutical development, global manufacturing, and supply chain capabilities. As part of the agreement, the companies will work on multiple solid tumor targets using antibodies from Regeneron’s VelocImmune® mice, and they also plan to develop complementary radio-diagnostic tools to help identify suitable patients and evaluate treatment responses.

John Lin, M.D., Ph.D., Senior Vice President of Oncology and Antibody Technology Research at Regeneron, explained that the company remains committed to pursuing the most effective therapeutic approaches across a variety of modalities. He noted that targeted radiopharmaceuticals represent an important and rapidly growing area in oncology, offering new possibilities for patients whose treatment needs are not adequately met by existing therapies.

Israel Lowy, M.D., Ph.D., Senior Vice President and Clinical Development Unit Head of Oncology at Regeneron, emphasized that Telix’s capabilities in radiopharmaceutical development are highly complementary to Regeneron’s antibody platforms. He highlighted that this collaboration allows Regeneron to expand into targeted radiopharmaceuticals and explore their use both as standalone treatments and in combination with the company’s immunotherapies. Lowy pointed out that this could be especially impactful in areas such as lung cancer, where Regeneron’s PD-1 inhibitor already plays a significant role in global treatment standards.

Telix Group CEO and Managing Director Christian Behrenbruch, D.Phil., stated that partnering with Regeneron provides a unique opportunity to advance the next generation of biologics-based radiopharmaceuticals. He noted that both companies share a strong commitment to precision oncology and are well positioned to develop new treatment options for patients with difficult-to-treat cancers.

Under the terms of the agreement, Telix will receive an upfront payment of $40 million USD from Regeneron in exchange for access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs. Regeneron has the option to expand the collaboration to include four additional programs, which would involve further upfront payments. The companies will share global commercialization costs and potential profits equally, and Telix will retain the option to co-promote certain future products. If Telix chooses not to co-fund development for a specific program, it may instead receive up to $535 million USD in development and commercial milestone payments, along with low double-digit royalties on net sales for that program.

The companies will also work together to develop diagnostic tools to support therapy selection, with Telix taking the lead on commercialization and Regeneron receiving a defined share of profits from these diagnostic assets.